AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART) - An African perspective

Transfusion and Apheresis Science

Volumn 37, Issue 1, 2007, Pages 63-70

  Sissolak, Gerhard ^c   Abayomi, Emmanuel Akinola ^c   Jacobs, Peter ^a,b,c  

^a The Department of Haematology   (South Africa)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; SOCIOECONOMICS; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, B-CELL; MALE; SARCOMA, KAPOSI; SOCIOECONOMIC FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 35348820471     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.04.010     Document Type: Article

References (50)

1. UNAIDS. Report on the Global AIDS Epidemic 2004. Geneva: UNAIDS; 2004.
2. Centers for Disease Control (CDC). Kaposi's sarcoma and pneumocystis pneumonia among homosexual men - New York and California. MMWR Morb Mortal Wkly Rep 30 (1981) 305-308
3. Goedert J.J., Cote T.R., Virgo P., Scoppa S.M., Kingma D.W., Gail M.H., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 (1998) 1833-1839
4. Sissolak G., and Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 10 (2005) 981-992
5. Raphael M., Borisch B., and Jaffe E.S. Lymphomas associated with infection by the human immunodeficiency virus (HIV). In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon 260-263 World Health Organization Classification of Tumours; 3
6. Levine A.M., Seneviratne L., Espina B.M., Wohl A.R., Tulpule A., Nathwani B.N., et al. Evolving characteristics of AIDS-related lymphoma. Blood 96 (2000) 4084-4090
7. Sparano J.A. Clinical aspects and management of AIDS-related lymphoma. Eur J Cancer 37 (2001) 1296-1305
8. Scadden D.T., Zon L.I., and Groopman J.E. Pathophysiology and management of HIV-associated hematologic disorders. Blood 74 (1989) 1455-1463
9. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92 (2000) 1823-1830
10. Mocroft A., Katlama C., Johnson A.M., Pradier C., Antunes F., Mulcahy F., et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 356 (2000) 291-296
11. Wolf T., Brodt H.R., Fichtlscherer S., Mantzsch K., Hoelzer D., Helm E.B., et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leukemia Lymphoma 46 (2005) 207-215
12. National HIV seroprevalence survey for South Africa 2003. South Africa: Department of Health; 2003. http://www.doh.gov.za/facts/index.html.
13. Patel M, Philip V, Turton D, Omar T, Candy J, Kosheva S, et al. Non-Hodgkin's lymphoma in HIV/AIDS era at Chris Hani Baragwanath Hospital, South Africa. In: Proceedings of the 2007 South African Haematology/Oncology symposium, Magaliesburg, South Africa.
14. Martinez-Maza O., and Breen E.C. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 14 (2002) 528-532
15. Cai X., Lu S., Zhang Z., Gonzalez C.M., Damania B., and Cullen B.R. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci USA 102 (2005) 5570-5575
16. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353 (2005) 1793-1801
17. Kieff E. Current perspectives on the molecular pathogenesis of virus-induced cancers in human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst Monogr 23 (1998) 7-14
18. Trono D. Picking the right spot. Science 300 (2003) 1670-1671
19. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
20. Gisselbrecht C., Oksenhendler E., Tirelli U., Lepage E., Gabarre J., Farcet J.P., et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. The French-Italian Cooperative Group. Am J Med 95 (1993) 188-196
21. Kaplan L.D., Straus D.J., Testa M.A., Von Roenn J., Dezube B.J., Cooley T.P., et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336 (1997) 1641-1648
22. Little R.F., Pittaluga S., Grant N., Steinberg S.M., Kavlick M.F., Mitsuya H., et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101 (2003) 4653-4659
23. Moore D.A.J., Benepal T., Portsmouth S., Gill J., and Gazzard B.G. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis 32 (2001) 469-476
24. Kaplan L.D., Lee J.Y., Ambinder R.F., Sparano J.A., Cesarman E., Chadburn A., et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106 (2005) 1538-1543
25. Ratner L., Lee J., Tang S., Redden D., Hamzeh F., Herndier B., et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19 (2001) 2171-2178
26. Bower M., McCall-Peat N., Ryan N., Davies L., Young A.M., Gupta S., et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104 (2004) 2943-2946
27. Stebbing J., Gazzard B., Mandalia S., Teague A., Materston A., Marvin V., et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 2177-2183
28. Tirelli U., Spina M., Gaidano G., Vaccher E., Franceschi S., and Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 14 (2000) 1675-1688
29. Walensky R.P., Paltiel A.D., Losina E., Mercincavage L.M., Schackman B.R., Sax P.E., et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 194 (2006) 11-19
30. Powles T., Matthews G., and Bower M. AIDS related systemic non-Hodgkin's lymphoma. Sex Transm Infect 76 (2000) 335-341
31. Sparano J.A., Lee S., Chen M.G., Nazeer T., Einzig A., Ambinder R.F., et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 22 (2004) 1491-1500
32. Tulpule A., Sherrod A., Dharmapala D., Young L.L., Espina B.M., Sanchez M.N., et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 26 (2002) 121-127
33. Cortes J., Thomas D., Rios A., Koller C., O'Brien S., Jeha S., et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94 (2002) 1492-1499
34. Oriol A., Ribera J.M., Esteve J., Sanz M.A., Brunet S., Garcia-Boyero R., et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 88 (2003) 445-453
35. Chetty R., Hlatswayo N., Muc R., Sabaratnam R., and Gatter K. Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. Histopathology 42 (2003) 605-609
36. Webster-Cyriaque J., Edwards R.H., Quinlivan E.B., Patton L., Wohl D., and Raab-Traub N. Epstein-Barr virus and human herpesvirus 8 prevalence in human immunodeficiency virus-associated oral mucosal lesions. J Infect Dis 175 (1997) 1324-1332
37. Cioc A.M., Allen C., Kalmar J.R., Suster C., Baiocchi R., and Nuovo G.J. Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8. Am J Surg Pathol 28 (2004) 41-46
38. Dong H.Y., Scadden D.T., de Leval L., Tang Z., Isaacson P.G., and Harris N.L. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 29 (2005) 1633-1641
39. Wang E.S., Straus D.J., Teruya-Feldstein J., Qin J., Portlock C., Moskowitz C., et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98 (2003) 1196-1205
40. Boulanger E., Gerard J., Gabarre J., Molina J.M., Rapp C., Abino J.F., et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23 (2005) 4372-4380
41. Simonelli C., Tedeschi R., Gloghini A., Bortolin M.T., Spina M., Bidoli E., et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis 40 (2005) 1022-1027
42. Hoffmann C., Tabrizian S., Wolf E., Eggers C., Stoehr A., Plettenberg A., et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15 (2001) 2119-2127
43. Newell M.E., Hoy J.F., Cooper S.G., DeGraaff B., Grulich A.E., Bryant M., et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 100 (2004) 2627-2636
44. Jacomet C., Girard P.M., Lebrette M.G., Farese V.L., Monfort L., and Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 11 (1997) 1725-1730
45. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
46. Dunleavy K., and Wilson W.H. The case for rituximab in AIDS-related lymphoma. Blood 107 (2006) 3014-3015
47. Krishnan A., Molina A., Zaia J., Smith D., Vasquez D., Kogut N., et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105 (2005) 874-878
48. Krishnan A.Y., Zaia J.A., Rossi J.J., Molina A., Li M., Lee W., et al. Autologous stem cell transplantation (ASCT) for AIDS-related lymphomas (ARL) and the potential role of HIV-resistant stem cells. Blood 108 11 (2006) 149a Abstr 491
49. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338 (1998) 853-860
50. Barclay L.R., Buskin S.E., Kahle E.M., and Aboulafia D.M. Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma 7 (2007) 272-279